Lindy Biosciences is a development stage protein therapeutic formulations company specializing in the creation of spherical, dense, and stable protein particles. These particles are designed for long-term storage and non-standard formulations, such as high concentration delivery of antibodies, encapsulation for sustained controlled release, and dry powder pulmonary delivery. The company operates in the biopharmaceutical market, serving clients who require advanced drug delivery solutions. Lindy Biosciences generates revenue through partnerships and licensing agreements with pharmaceutical companies seeking to enhance their biologic formulations. The core technology, known as Microglassification, allows for the production of high concentration, low viscosity suspensions of biologics suitable for subcutaneous injection. This technology addresses the need for more efficient and patient-friendly drug delivery methods, particularly in the field of protein therapeutics.

Keywords: protein particles, biologics, subcutaneous injection, high concentration, low viscosity, drug delivery, Microglassification, antibodies, encapsulation, pulmonary delivery.